Last reviewed · How we verify
Treatment of osteoporosis in postmenopausal women at high risk of fracture — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Duavee | conjugated-estrogens-bazedoxifene | Pfizer | Estrogen [EPC] | estrogen receptors α and β | 2013-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 1 drug in Treatment of osteoporosis in postmenopausal women at high risk of fracture
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Treatment of osteoporosis in postmenopausal women at high risk of fracture:
- Treatment of osteoporosis in postmenopausal women at high risk of fracture treatment updates — RSS
- Treatment of osteoporosis in postmenopausal women at high risk of fracture treatment updates — Atom
- Treatment of osteoporosis in postmenopausal women at high risk of fracture treatment updates — JSON
Cite this brief
Drug Landscape (2026). Treatment of osteoporosis in postmenopausal women at high risk of fracture — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/treatment-of-osteoporosis-in-postmenopausal-women-at-high-risk-of-fracture. Accessed 2026-06-10.
Related
- Treatment of osteoporosis in postmenopausal women at high risk of fracture full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing